About Alithea Genomics
Alithea Genomics is a Healthcare company based in Lausanne (Switzerland) founded in 2020 by Bart Deplancke, Daniel Alpern, and Riccardo Dainese. Transcriptomics solutions are provided for research and biomarker discovery. It operates on a Professional Services and Direct-to-Consumer (D2C) model in Healthcare and Technology sectors. Alithea Genomics has raised $8.13 million across 6 funding rounds from investors including Novalis Biotech, TechU Ventures and FIT. Its website alitheagenomics.com draws about 13 thousand monthly visits. Alithea Genomics offers products and services including MERCURIUSâ„¢ DRUG-seq, MERCURIUSâ„¢ FLASH-seq, and MERCURIUSâ„¢ BRB-seq. Its focus areas include Biotechnology and Genomics. Its legal entity is Alithea Genomics SA.
Company details
RNA sequencing technologies and services are developed by Alithea Genomics for applications in drug screening, biomarker discovery, fundamental research, and crop science. Various sample types including cells, organoids, tissues, and blood are supported by their solutions. High-throughput and extraction-free methods are utilized to enable cost-effective and comprehensive gene expression studies. Sectors such as biotechnology and healthcare are primarily served with innovative kits and services.
- Headquarters Lausanne, Switzerland
- Founders Bart Deplancke, Daniel Alpern, Riccardo Dainese
- SectorsHealthcareTechnology
- Phone•••• ••••
- Website alitheagenomics.com
- Social LinkedIn X
- Legal Name Alithea Genomics Sa
- Total Equity Funding$8.13M (USD)
in 6 rounds
- Latest Funding Round$3.9M (USD), Seed
Mar 2026
- InvestorsNovalis Biotech
& 4 more
Products & Services of Alithea Genomics
Alithea Genomics offers a comprehensive portfolio of products and services, including MERCURIUS™ DRUG-seq, MERCURIUS™ FLASH-seq, and MERCURIUS™ BRB-seq.
Extraction-free kits are provided for large-scale compound screening.
Ultra-sensitive kits are offered for single-cell RNA analysis.
Cost-effective kits are designed for bulk RNA sequencing.
Funding Insights of Alithea Genomics
Alithea Genomics has successfully raised a total of $8.13M across 6 strategic funding rounds. The most recent funding activity was a Seed round of $3.9 million completed in March 2026. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
- Total Funding $8.13M
- Total Rounds 6
- Last Round Seed — $3.9M
- First Round $10,256
(Apr 2020)
- Investors Count 5
All 6 funding rounds of Alithea Genomics with amounts and investors; the two latest post-money valuations are shown, the rest are part of the premium plan.
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Mar 2026 | $3.9M | Seed | – | – | |
| Mar 2024 | $3.2M | Seed | – | Novalis Biotech | |
| Mar 2023 | $539,145 | Debt – Conventional | – | – | |
| May 2022 | $1.03M | Seed | – | Novalis Biotech | – |
| Jul 2020 | $109,621 | Grant | – | – | |
| Apr 2020 | $10,256 | Grant | – | – |
5 investors in total: 5 institutional.
Investors in Alithea Genomics
Alithea Genomics has secured backing from 5 investors, including venture fund and institutional investors. Prominent investors backing the company include Novalis Biotech, TechU Ventures and FIT.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
Early-stage venture capital investment is provided in life sciences. | noval.is | Ghent, Belgium | ||
TechU Ventures is involved in unspecified technology ventures. | techuventures.com | |||
Grants and loans are provided by FIT for innovative startups. | 1994 | fondation-fit.ch | Lausanne, Switzerland | |
University backed startup accelerator | venturekick.ch | Schlieren, Switzerland | ||
| zkb.ch |
Investor details for Alithea Genomics
The complete investor list, round-by-round participation and investor portfolios require an active premium plan.
- Complete investor list
- Round participation
- Investor portfolios
- Co-investor network
Verified entity values are shown only after access is granted.
People of Alithea Genomics
13 people are tracked at Alithea Genomics (3 in leadership, 6 in board & advisors, 4 in team).
| Name | Role | Group |
|---|---|---|
Bart Deplancke | Co-Founder | Leadership |
Daniel Alpern | Co-Founder | Leadership |
Riccardo Dainese | Co-Founder | Leadership |
Jan Van Den Berghe | Board Member | Board & advisors |
Kaspar Binz | Board Member | Board & advisors |
Roger Kung | Board Member | Board & advisors |
Reto Hartmann | Advisor | Board & advisors |
Frederik Decouttere | Chairman of the Board | Board & advisors |
Eric Barray | Advisor | Board & advisors |
Marine Vallez | Senior R&d Engineer | Team |
Clément Quan | Account Manager | Team |
Diana S. | Product Manager, Bioinformatics Solutions | Team |
Alix Buu-Hoang | NGS Service Manager | Team |
Complete people profiles for Alithea Genomics
Full employee and board profiles, team structure, tenure and professional contact details require an active premium plan.
- Full employee list
- Team structure
- Board tenure
- Professional contacts
Verified entity values are shown only after access is granted.
Timeline of Alithea Genomics
3 dated milestones of Alithea Genomics across 6 years, from founding to its latest funding, stage changes and deals.
- Founded Alithea Genomics is founded.
- Funding First funding round of $10K.
- Funding Latest funding round, Seed, of $3.9M.
Web traffic of Alithea Genomics
The website of Alithea Genomics (alitheagenomics.com) receives about 12.5K visits a month.
- Monthly visits12.5K
▼ 5.9% vs previous month
Websites whose visitors overlap most with Alithea Genomics. Affinity shows how closely the audiences match.
| Website | Domain | Audience affinity | Monthly visits | Global rank | Profile |
|---|---|---|---|---|---|
geneinfinity.org | geneinfinity.org | 100% | #680,187 | – | |
| scdiscoveries.com | 92% | 22.8K | #1,249,234 | View details | |
| lcsciences.com | 91% | #2,732,434 | View details | ||
| sib.swiss | 81% | 185.7K | #263,793 | View details | |
cd-genomics.com | cd-genomics.com | 81% | #300,823 | – | |
| •••••••••• | ••••••.com | ••% | •.•M | #••••• | – |
| •••••••••• | ••••••.com | ••% | •.•M | #••••• | – |
| •••••••••• | ••••••.com | ••% | •.•M | #••••• | – |
All 11 similar websites and full traffic analytics for Alithea Genomics
The complete similar-websites list, audience overlap and engagement analytics require an active premium plan.
- 11 similar websites
- Audience overlap
- Engagement analytics
- Traffic by brand
Verified entity values are shown only after access is granted.
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Related news about Alithea Genomics
Complete news archive for Alithea Genomics
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Frequently Asked Questions about Alithea Genomics
Alithea Genomics was founded in 2020.
Alithea Genomics is headquartered in Lausanne, Switzerland. It is registered at Lausanne, Vaud, Switzerland.
Alithea Genomics is a funded company, having raised a total of $8.13M across 6 funding rounds to date. The company's 1st funding round was a Grant of $10.26K, raised on Apr 2020.
RNA sequencing technologies and services are developed by Alithea Genomics for applications in drug screening, biomarker discovery, fundamental research, and crop science. Various sample types including cells, organoids, tissues, and blood are supported by their solutions. High-throughput and extraction-free methods are utilized to enable cost-effective and comprehensive gene expression studies. Sectors such as biotechnology and healthcare are primarily served with innovative kits and services.
Alithea Genomics offers MERCURIUSâ„¢ DRUG-seq, MERCURIUSâ„¢ FLASH-seq, and MERCURIUSâ„¢ BRB-seq.
Alithea Genomics has 5 investors. Key investors include Novalis Biotech, TechU Ventures, FIT, Venture Kick, and Zurcher Kantonalbank.
Alithea Genomics operates through Alithea Genomics Sa.